Citation

Johnston SS, Alexander AH, Masters ET, Mardekian J, Semel D, Malangone-Monaco E, Riehle E, Wilson K, Sadosky A. J. Occup. Environ. Med. 2016; 58(11): 1087-1097.

Affiliation

Truven Health Analytics, Bethesda, Maryland (Mr Johnston, Ms Malangone-Monaco, Ms Riehle, Ms Wilson); and Pfizer Inc., New York, New York (Ms Alexander, Ms Masters, Drs Mardekian, Semel, Sadosky).

Copyright

(Copyright © 2016, Lippincott Williams and Wilkins)

DOI

10.1097/JOM.0000000000000865

PMID

27820758

Abstract

OBJECTIVE: To compare 12-month healthcare costs between employees with versus without diagnosed opioid abuse within 12 months after an injury-related workers' compensation (WC) or short-term disability (STD) claim.

METHODS: Retrospective study using 2003 to 2014 US insurance claims linked to administrative data on WC/STD claims. Multivariable models compared healthcare costs between employees with versus without diagnosed opioid abuse.

RESULTS: Study included 107,975 opioid-treated employees with an injury-related WC or STD claim. Mean number of opioid prescription fills and adjusted total healthcare costs were substantially greater in employees with diagnosed opioid abuse versus without (WC: 13.4 vs. 4.5, P < 0.001; $18,073 vs. $8470, P < 0.001; STD: 13.7 vs. 4.5, P < 0.001; $25,693 vs. $14,939, P < 0.001).

CONCLUSION: Opioids are commonly prescribed to employees with injury-related WC/STD claims. Employers may benefit from proactively addressing the issue of opioid abuse in these populations.

Language: en